Heart Failure With Preserved Ejection Fraction: An Evolving Understanding.
| Autor: | Tah S; Surgery, Beckley Appalachian Regional Healthcare (ARH) Hospital, Beckley, USA.; Surgery, Saint James School of Medicine, Arnos Vale, VCT., Valderrama M; Medicine, Pontificia Universidad Javeriana, Cali, COL., Afzal M; Medicine, Fatima Jinnah Medical University, Lahore, PAK., Iqbal J; Neurosurgery, Mayo Hospital, Lahore, PAK., Farooq A; Internal Medicine, Dr. Ruth Pfau Hospital, Karachi, PAK., Lak MA; Internal Medicine, Combined Military Hospital, Lahore, PAK., Gostomczyk K; Medicine, Collegium Medicum Nicolaus Copernicus University, Bydgoszcz, POL., Jami E; Internal Medicine, Herat Regional Hospital, Herat, AFG., Kumar M; Medicine, Sardar Patel Medical College, Bikaner, IND., Sundaram A; Internal Medicine, Kasturba Medical College, Manipal, IND., Sharifa M; Medicine, University of Aleppo, Aleppo, SYR., Arain M; Internal Medicine, Civil Hospital Karachi, Karachi, PAK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Sep 28; Vol. 15 (9), pp. e46152. Date of Electronic Publication: 2023 Sep 28 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.46152 |
| Abstrakt: | Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have signs and symptoms of HF due to high left ventricular (LV) filling pressure despite normal or near normal LV ejection fraction. It is more common than HF with reduced ejection fraction (HFrEF), and its diagnosis and treatment are more challenging than HFrEF. Although hypertension is the primary risk factor, coronary artery disease and other comorbidities, such as atrial fibrillation (AF), diabetes, chronic kidney disease (CKD), and obesity, also play an essential role in its formation. This review summarizes current knowledge about HFpEF, its pathophysiology, clinical presentation, diagnostic challenges, current treatments, and promising novel treatments. It is essential to continue to be updated on the latest treatments for HFpEF so that patients always receive the most therapeutic treatments. The use of GnRH agonists in the management of HFpEF, infusion of Apo a-I nanoparticle, low-level transcutaneous vagal stimulation (LLTS), and estrogen only in post-menopausal women are promising strategies to prevent diastolic dysfunction and HFpEF; however, there is still no proven curative treatment for HFpEF yet. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Tah et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|